BLA 761085 · Evolus INC
Jeuveau
Prabotulinumtoxina-Xvfs · Injection · Acetylcholine Release Inhibitor; Neuromuscular Blocker
NovelLast checked: Nov 20, 2026Latest source record: Jul 12, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Feb 1, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
0 Phase 3, 2 recruiting
FAERS reports
3,779
61 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellar lines. [ See Warnings and Precautions ( 5.1 ) ] WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life...
What it is approved for
From the label in effect Apr 28, 2023.
JEUVEAU is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. JEUVEAU is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients ( 1 )
Mechanism: JEUVEAU blocks neuromuscular transmission by binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. When injected intramuscularly at therapeutic doses, JEUVEAU produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 1, 2019 Original approval · Type 1 - New Molecular Entity NovelLabelMedication GuideLetter
1 products under this application
- JEUVEAU · PRABOTULINUMTOXINA-XVFS 100 UNITS · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Prabotulinumtoxina" as an intervention, any sponsor and status, largest first.
- Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in AdultsPivotal-lookingCompleted
AEON Biopharma, Inc.Industry
NCT04845178 · 797 participants · Start Mar 1, 2021 · Primary completion Jun 19, 2024
Drug: ABP-450; Placebo · For: Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Tempe, Arizona · 62 sites in all
- Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine PreventionPivotal-lookingTerminated
AEON Biopharma, Inc.Industry
NCT05016661 · 466 participants · Start Oct 19, 2021 · Primary completion Jul 31, 2024
Drug: ABP-450 · For: Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Tempe, Arizona · 55 sites in all
- Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar RhytidesPivotal-lookingRecruiting
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
NCT06448676 · 325 participants (planned) · Start Feb 2, 2026 · Primary completion Jan 15, 2027
Drug: Botulinum toxin type A · For: Wrinkle; Glabellar Frown Lines; Glabellar Furrowing
Sites: Amsterdam, Netherlands; Eindhoven, Netherlands; Utrecht, Netherlands
- Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar LinesPivotal-lookingCompleted
Evolus, Inc.Industry
NCT05320393 · 154 participants · Start Mar 30, 2022 · Primary completion May 22, 2023
Drug: PrabotulinumtoxinA-Xvfs; OnabotulinumtoxinA and 1 more · For: Glabellar Frown Lines
Sites: Boca Raton, Florida
- Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella AreaPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT05167864 · 143 participants · Start Mar 4, 2022 · Primary completion Jun 30, 2023
Drug: Onabotulinumtoxina for Injection; Abobotulinumtoxina for Injection and 2 more · For: Cosmetic Techniques
Sites: Philadelphia, Pennsylvania
Recep Tayyip Erdogan UniversityAcademic, hospital or other
NCT07452510 · 72 participants · Start Jan 9, 2026 · Primary completion Apr 8, 2026
Drug: PrabotulinumtoxinA; Abobotulinumtoxina · For: Bruxism; Sleep Bruxism, Adult; Awake Bruxism and 2 more
Sites: Rize, Turkey (Türkiye)
- A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical DystoniaCompleted
AEON Biopharma, Inc.Industry
NCT04849988 · 61 participants · Start Mar 29, 2021 · Primary completion Jul 11, 2022
Drug: ABP-450; Placebo · For: Cervical Dystonia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fountain Valley, California · 21 sites in all
AEON Biopharma, Inc.Industry
NCT04871451 · 51 participants · Start Jul 27, 2021 · Primary completion Jul 24, 2023
Drug: ABP-450 · For: Cervical Dystonia
Sites: Phoenix, Arizona; Fountain Valley, California; Fresno, California · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,590
- off label use1,315
- therapeutic product effect decreased715
- drug effect less than expected469
- headache171
- injection site pain114
- patient dissatisfaction with treatment105
- injection site swelling99
- eyelid ptosis73
- inappropriate schedule of product administration72
- injection site erythema67
- product preparation issue59
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1,156 |
| 2020 | 749 |
| 2021 | 199 |
| 2022 | 175 |
| 2023 | 273 |
| 2024 | 326 |
| 2025 | 406 |
| 2026 | 495 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Botulinum toxin type A for facial wrinkles.
Camargo CP, Xia J, Costa CS, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- PrabotulinumtoxinA-xvfs for the Treatment of Moderate-to-Severe Glabellar Lines.
Gadarowski MB, Ghamrawi RI, Taylor SL, et al. · Ann Pharmacother 2021 · Systematic Review
- PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data.
Solish N, Ascher B, Avelar RL, et al. · Aesthet Surg J 2022 · Clinical Trial, Phase III
- Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study.
Seok J, Koh YG, Hong JK, et al. · Dermatol Surg 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Kaufman-Janette J, Avelar RL, Biesman BS, et al. · Aesthet Surg J 2021 · Clinical Trial, Phase II, Multicenter Study
- PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color: Post Hoc Analyses of the US Phase III Clinical Study Data.
Taylor SC, Grimes PE, Joseph JH, et al. · Dermatol Surg 2021 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
Sponsor: Evolus INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.